

# Molly A Taylor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6169189/publications.pdf>

Version: 2024-02-01

13  
papers

920  
citations

1039880

9  
h-index

1372474

10  
g-index

13  
all docs

13  
docs citations

13  
times ranked

2034  
citing authors

#	ARTICLE	IF	CITATIONS
1	TGF- $\beta$ 2 upregulates miR-181a expression to promote breast cancer metastasis. <i>Journal of Clinical Investigation</i> , 2013, 123, 150-163.	3.9	264
2	The Pathophysiology of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor- $\beta$ 2 in Normal and Malignant Mammary Epithelial Cells. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2010, 15, 169-190.	1.0	202
3	Lysyl Oxidase Contributes to Mechanotransduction-Mediated Regulation of Transforming Growth Factor- $\beta$ 2 Signaling in Breast Cancer Cells. <i>Neoplasia</i> , 2011, 13, 406-412.	2.3	85
4	Functional Roles for Exosomal MicroRNAs in the Tumour Microenvironment. <i>Computational and Structural Biotechnology Journal</i> , 2017, 15, 8-13.	1.9	72
5	Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. , 2019, 7, 328.		65
6	PI3K $\beta$ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity. , 2018, 6, 158.		62
7	Therapeutic opportunities for targeting microRNAs in cancer. <i>Molecular and Cellular Therapies</i> , 2014, 2, 30.	0.2	36
8	Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 86313-86325.	0.8	34
9	Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. <i>Oncimmunology</i> , 2018, 7, e1458810.	2.1	30
10	VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. <i>Journal of Hematology and Oncology</i> , 2021, 14, 186.	6.9	27
11	Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. , 2022, 10, e003892.		26
12	Circulating MicroRNAs as Biomarkers and Mediators of Cell-Cell Communication in Cancer. <i>Biomedicines</i> , 2015, 3, 270-281.	1.4	10
13	Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3K $\beta$ Inhibition. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1080-1091.	1.9	7